GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Omeros Corp (FRA:3O8) » Definitions » Payments to Suppliers for Goods and Services

Omeros (FRA:3O8) Payments to Suppliers for Goods and Services


View and export this data going back to 2009. Start your Free Trial

What is Omeros Payments to Suppliers for Goods and Services?

Payments to Suppliers for Goods and Services only applicable to companies reporting Cash Flow from Operations in direct method.


Omeros (FRA:3O8) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Omeros Corp (FRA:3O8) » Definitions » Payments to Suppliers for Goods and Services
Traded in Other Exchanges
Address
201 Elliott Avenue West, Seattle, WA, USA, 98119
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.